Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California. Show more
11400 West Olympic Boulevard, Los Angeles, CA, 90064, United States
Market Cap
972.5M
52 Wk Range
$1.94 - $13.76
Previous Close
$13.66
Open
$13.66
Volume
1,414,835
Day Range
$12.90 - $13.80
Enterprise Value
741.7M
Cash
232.1M
Avg Qtr Burn
-11.74M
Insider Ownership
17.13%
Institutional Own.
78.88%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|